Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL177880 (Pamoic Acid) |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
DNA polymerase beta in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2392] [GtoPdb: 3231] [UniProtKB: P06746] | ||||||||
ChEMBL | Inhibition of DNA polymerase beta (unknown origin) | B | 5.05 | pIC50 | 9000 | nM | IC50 | J Med Chem (2013) 56: 5182-5197 [PMID:23713606] |
GPR35/G-protein coupled receptor 35 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1293267] [GtoPdb: 102] [UniProtKB: Q9HC97] | ||||||||
ChEMBL | Competitive binding affinity to Nluc-fused human GPR35 expressed in CHO-K1 cells assessed as inhibition constant using furimazine as substrate incubated for 30 mins followed by substrate addition by in presence of 10-(4-(2-(4-(4-((2,8-dicarboxy-6-hydroxy-10-methylpyrido[3,2-g]quinolin-4-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-5,5-difluoro-2,7,9-trimethyl-5H-imidazo[1,2-c]pyrrolo[2,1-f][1,3,2]diazaborinin-6-ium-5-uide | B | 7.64 | pKi | 23 | nM | Ki | ACS Med Chem Lett (2023) 14: 411-416 [PMID:37077394] |
ChEMBL | Competitive binding affinity to Nluc-fused human GPR35 expressed in CHO-K1 cells assessed as inhibition constant using furimazine as substrate incubated for 30 mins followed by substrate addition by in presence of 20 nM of 10-(4-(2-(4-(4-((2,8-dicarboxy-6-hydroxy-10-methylpyrido[3,2-g]quinolin-4-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-5,5-difluoro-2,7,9-trimethyl-5H-imidazo[1,2-c]pyrrolo[2,1-f][1,3,2]diazaborinin-6-ium-5-uide | B | 7.83 | pKi | 14.9 | nM | Ki | ACS Med Chem Lett (2023) 14: 411-416 [PMID:37077394] |
ChEMBL | Displacement of [3H]PSB-13253 from human recombinant GPR35 exprssed in CHO cells by liquid scintillation counting analysis | B | 7.94 | pKi | 11.5 | nM | Ki | J Med Chem (2013) 56: 7084-7099 [PMID:23888932] |
ChEMBL | Competitive binding affinity to Nluc-fused human GPR35 expressed in CHO-K1 cells assessed as inhibition constant using furimazine as substrate incubated for 30 mins followed by substrate addition by in presence of 50 nM of 10-(4-(2-(4-(4-((2,8-dicarboxy-6-hydroxy-10-methylpyrido[3,2-g]quinolin-4-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-5,5-difluoro-2,7,9-trimethyl-5H-imidazo[1,2-c]pyrrolo[2,1-f][1,3,2]diazaborinin-6-ium-5-uide | B | 7.99 | pKi | 10.3 | nM | Ki | ACS Med Chem Lett (2023) 14: 411-416 [PMID:37077394] |
ChEMBL | Competitive binding affinity to Nluc-fused human GPR35 expressed in CHO-K1 cells assessed as inhibition constant using furimazine as substrate incubated for 30 mins followed by substrate addition by in presence of 100 nM of 10-(4-(2-(4-(4-((2,8-dicarboxy-6-hydroxy-10-methylpyrido[3,2-g]quinolin-4-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-5,5-difluoro-2,7,9-trimethyl-5H-imidazo[1,2-c]pyrrolo[2,1-f][1,3,2]diazaborinin-6-ium-5-uide | B | 8.02 | pKi | 9.6 | nM | Ki | ACS Med Chem Lett (2023) 14: 411-416 [PMID:37077394] |
ChEMBL | Competitive binding affinity to Nluc-fused human GPR35 expressed in CHO-K1 cells assessed as inhibition constant using furimazine as substrate incubated for 30 mins followed by substrate addition by in presence of 40 nM of 10-(4-(2-(4-(4-((2,8-dicarboxy-6-hydroxy-10-methylpyrido[3,2-g]quinolin-4-yl)oxy)butyl)-1H-1,2,3-triazol-1-yl)ethoxy)phenyl)-5,5-difluoro-2,7,9-trimethyl-5H-imidazo[1,2-c]pyrrolo[2,1-f][1,3,2]diazaborinin-6-ium-5-uide | B | 8.05 | pKi | 8.9 | nM | Ki | ACS Med Chem Lett (2023) 14: 411-416 [PMID:37077394] |
ChEMBL | Agonist activity at C-terminal beta-galactosidase tagged human recombinant GPR35 expressed in CHO cells after 90 mins by beta-arrestin recruitment assay | B | 5.92 | pEC50 | 1200 | nM | EC50 | J Med Chem (2013) 56: 7084-7099 [PMID:23888932] |
ChEMBL | Agonist activity at GPR-35 (unknown origin) by beta-arrestin assay | B | 5.92 | pEC50 | 1200 | nM | EC50 | ACS Med Chem Lett (2023) 14: 411-416 [PMID:37077394] |
ChEMBL | Agonist activity at human GPR35 receptor expressed in HEK293T cells co-expressing beta-arrestin2 assessed as induction of beta-arrestin2 recruitment by BRET assay | F | 6.3 | pEC50 | 500 | nM | EC50 | J Med Chem (2021) 64: 2634-2647 [PMID:33630609] |
ChEMBL | Agonist activity at human GPR35 expressed in CHO-K1 cells after 90 mins by beta-arrestin 2 recruitment assay | B | 6.3 | pEC50 | 500 | nM | EC50 | J Med Chem (2017) 60: 362-372 [PMID:27976894] |
GtoPdb | - | - | 7.29 | pEC50 | - | - | - | Biochem J (2010) 432: 451-9 [PMID:20919992] |
ChEMBL | Agonist activity at human GPR35 expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase reporter gene assay | B | 7.3 | pEC50 | 50 | nM | EC50 | J Med Chem (2013) 56: 5182-5197 [PMID:23713606] |
ChEMBL | Agonist activity at GPR-35 (unknown origin) expressed in HT-29 cells by DMR assay | B | 8.52 | pEC50 | 3 | nM | EC50 | ACS Med Chem Lett (2023) 14: 411-416 [PMID:37077394] |
ChEMBL | Agonist activity at human GPR35 by DMR assay | B | 8.68 | pEC50 | 2.1 | nM | EC50 | J Med Chem (2013) 56: 7084-7099 [PMID:23888932] |
ChEMBL | Agonist activity at human GPR35 expressed in CHO-K1 cells by DMR assay | B | 8.7 | pEC50 | 2 | nM | EC50 | J Med Chem (2017) 60: 362-372 [PMID:27976894] |
ChEMBL | Agonist activity at human GPR35 receptor expressed in HT-29 cells assessed as dynamic mass redistribution response measured for 60 mins by DMR assay | F | 8.7 | pEC50 | 2 | nM | EC50 | J Med Chem (2021) 64: 2634-2647 [PMID:33630609] |
GPR35 in Rat [GtoPdb: 102] [UniProtKB: Q33BM1] | ||||||||
GtoPdb | - | - | 5 | pEC50 | - | - | - | Biochem J (2010) 432: 451-9 [PMID:20919992] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]